Global Cell-Free DNA (cfDNA) Markets Report 2016 Featuring Illumina and Thermo Fisher Scientific - Research and Markets

News provided by

Dec 22, 2016, 11:10 ET

DUBLIN, Dec 22, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Cell-Free DNA (cfDNA) Markets: Consumables, Systems/Hardware, Services" report to their offering.

Cell-Free DNA (cfDNA) Markets: Consumables, Systems/Hardware, Services examines the opportunity for cell-free DNA analysis instruments, consumables, kits, and related software.

Current sales analysis and projections to 2021 are provided, as well as measurements of market growth; sales by product type; sales revenues of major competitors in the market; and geographic performance in North America, Europe, Asia-Pacific, and the rest of the world. Intellectual Property Litigation in the cfDNA analysis market is discussed, as well as collaborations.

Illumina and Thermo Fisher Scientific are among the manufacturers discussed in the report's competitor analysis. Market challenges and responses to these challenges are also presented

Key Topics Covered:

Chapter 1: Executive Summary

NIPT, Oncology Leading Market Forward
Sensitivity Benefits of dPCR, qPCR, NGS
Challenges, Biological and Technologies Limitations
Scope and Methodology

Chapter 2: Introduction

NIPT Companies, Others Shifting Strategies to Cancer
Expanding Clinical Adoption Sustains High Growth
Government Initiatives -- Cancer Moonshot, Blood Profiling Atlas
Mergers, Acquisitions, Equity Investments Increasing
China Becoming Major Player in Market
Personalized, Proactive Medicine Gaining Momentum
Expected Sequencer Platforms Stalled or Cancelled
Significant Efforts in Automation, Miniaturization
Regulatory Situation Unclear But Evolving Somewhat

Chapter 3: cfDNA Analysis Products

cfDNA Reagents, Consumables, and Kits
cfDNA Systems and Software
cfDNA NIPT Products and Services
cfDNA in Oncology, Transplantation and Other Diseases
cfDNA Other Products
Recent Product/ Service Introductions

Chapter 4: Market Analysis

Revenues Forecast
Market Size and Forecast
cfDNA Clinical Diagnostics Market
cfDNA Market by Region
Revenues by Product Type
Illumina Sequencing Revenues as Indicator

Chapter 5: cfDNA Instruments and Consumables Competitive Analysis

Chapter 6: Intellectual Property and Litigation

Sequenom, Several NIPT Companies Fighting
Ariosa Diagnostics (Roche) Files Suit Against Sequenom
Natera Sues Sequenom; Sequenom Sues Natera
Verinata Health and Stanford File Against Sequenom
Verinata Health Against Ariosa and LabCorp
Illumina Sues Ariosa Diagnostics for NIPT Test
Illumina Sues Premaitha Health for NIPT Test
Illumina Sues Premaitha and Ariosa Partners
Sequenom and Illumina Settle and Pool Patents
Sequenom Petitions Supreme Court
Illumina Sues Qiagen for GeneReader System
Illumina's Conflicts with Oxford Nanopore
Enzo Biochem Brings Suit Against Numerous Companies
Cell-Free DNA Markets
RainDance Technologies Sues 10X Genomics
10X Genomics' Dispute with Bio-Rad
Sequenom Shareholder Sues Over Price Capping
Helicos' Patent Infringement Suit Against PacBio, Life Technologies, and Illumina
Illumina's Two Lawsuits Against Complete Genomics for Infringement
Life Technologies and Illumina Dispute Over Amplification on Solid Surfaces
Enzo Biochem Disputes Sequencing Patents
LabCorp's Esoterix Sues Life Technologies
Genetic Technologies Sues Several Firms for Infringement of Haplotype Determination Technique